StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research note published on Monday morning.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group increased their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research note on Tuesday, June 4th. Cantor Fitzgerald reissued an overweight rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. JPMorgan Chase & Co. reissued a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Finally, Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an outperform rating in a report on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $50.67.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $43.61 on Monday. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $49.06. The firm has a market cap of $2.48 billion, a P/E ratio of -6.90 and a beta of 0.77. The business’s fifty day moving average is $37.98 and its two-hundred day moving average is $30.44.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. During the same quarter in the prior year, the firm posted ($1.47) earnings per share. The firm’s revenue for the quarter was up 46.0% compared to the same quarter last year. On average, equities research analysts predict that Agios Pharmaceuticals will post -2.68 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the transaction, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AGIO. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. boosted its position in Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 5,040 shares during the last quarter. NEOS Investment Management LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 942 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in Agios Pharmaceuticals by 31.8% during the fourth quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 2,900 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.